Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Newly Diagnosed SLE Patients Have a Greater Risk of Cardiovascular Disease

Arthritis Care & Research  |  June 4, 2017

New research has examined the risk of cardiovascular disease (CVD), as well as myocardial infarction and ischemic stroke, for patients with systemic lupus erythematosus (SLE) in a large-scale population-based study. Researchers found that patients with SLE have a greater than two-fold increased risk of developing CVD. This risk is greatest during the first year after diagnosis and remains elevated for at least five years…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Arthritis Care & ResearchCardiovascular diseasecardiovascular eventMyocardial infarctionSLEstrokesystemic lupus erythematosus (SLE)

A Look at CPT Codes for Prolonged Services

From the College  |  May 31, 2017

In the 2017 Medicare physician fee schedule, the CMS officially activated CPT codes 99358 and 99359 as reimbursable codes for non-face-to-face prolonged services performed in the office or outpatient setting, hospital or nursing facility by physicians or other qualified health practitioners (not clinical staff). The CPT codes are defined as 99358: Prolonged evaluation and management service…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:CPT codesCPT codes 99358 and 99359

NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

Michele B. Kaufman, PharmD, BCGP  |  May 29, 2017

NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…

Filed under:AnalgesicsDrug Updates Tagged with:canagliflozindiabetesFDAFood and Drug AdministrationheartMyocardial infarctionNonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDs

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  May 22, 2017

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFood and Drug Administrationinfliximabinfliximab-abdaOsteoporosis

Optical Workings: Specialists Must Communicate to Treat Eye Disease

Richard Quinn  |  May 19, 2017

In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:eyeEye diseaseInflammatory Eye DiseaseOphthalmologistUveitis

Trainees Discuss Pros, Cons of Rheumatology Residency Rotation

Katarzyna Gilek-Seibert, MD, with Anais Ovalle, MD, Elias Jabbour, MD, Heather Ferri, DO, & Gabrielle Thottam, MD  |  May 18, 2017

One day not too long ago, right smack in the middle of Thanksgiving and Christmas, I was sitting at the roundtable of our conference room, also known as the solarium due to its sunny disposition. The spirit was high, and we all felt like we could bring some joy to the clinic that day. I…

Filed under:Education & TrainingLegislation & AdvocacyWorkforce Tagged with:Educationfellowmedical residentrheumatologistrheumatologyTraining

How Tuberculosis Has Shaped Medicine and Society

Simon M. Helfgott, MD  |  May 17, 2017

Pathologists are legendary for blending their work product with the culinary arts. Through the years, their use of delectable foods as descriptors has created a clever way to indelibly link in the minds of clinicians the histopathologic observations of disease with an assortment of these tasty foods: There is the depiction of an apple green…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Caseation necrosisHistoryImmunologyrheumatologistrheumatologyTreatmentTuberculosis

BYUNG H. BAN, DO

Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab

Byung H. Ban, DO, Jayne L. Crowe, MD, & Robert M. Graham, MD  |  May 17, 2017

Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…

Filed under:Conditions Tagged with:adverse eventsaortitiscase reportClinicalCorticosteroidsdrugImmunologyipilimumabManagementoutcomepatient carerheumatologistrheumatologytherapyTreatment

Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models

Carina Stanton  |  May 17, 2017

The work of health policy reform is a marathon, not a sprint. The ACR is encouraged by the forward progress being made in collaboration with the American Medical Association and other physician-led organizations within the Healthcare Leaders for Accountable Innovation in Medicare and Medicaid coalition (known as the AIM coalition) to advocate for physicians’ ability…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Center for Medicare and Medicaid Innovation (CMMI)Healthcare Leaders for Accountable Innovation in Medicare andpayment models

Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 16, 2017

Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis

  • « Previous Page
  • 1
  • …
  • 183
  • 184
  • 185
  • 186
  • 187
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences